The regulatory role of synaptotagmin-like protein 2 (SYTL2) in prostate cancer (PCa) cell migration is a research area worthy of attention. As an effector of small GTPase, SYTL2 may regulate cell migration and invasiveness by affecting intracellular signal transduction pathways. Studies have shown that the expression level of SYTL2 in tumor cells may be associated with tumor progression, metastatic ability, and patient prognosis.
SYTL2 may affect cell morphology and motility by interacting with cytoskeletal proteins. SYTL2 may regulate some key signaling pathways, such as Rho family GTPases, PI3K/Akt pathways, which play an important role in cell migration and survival. SYTL2 may participate in cell membrane transport and vesicle transport processes, affect the localization and activity of cell adhesion factors, and thus regulate the migration ability of cells. It may affect the migration of cancer cells by regulating the interaction with surrounding cells or matrix.
Fig 1. The expression level of Synaptotagmin-like Protein 2 (SYTL2) is associated with metastasis and poor prognosis in PCa patients (Li, Z., et al. 2023).
The protein forms part of the synaptosome-like protein family while participating in numerous cellular functions which primarily include vesicle transport and membrane fusion. Some tumors show abnormal SYTL2 expression which may increase cell migration and invasion. The precise function of SYTL2 in prostate cancer remains unclear but research is investigating its utility as a tumor biomarker or therapeutic target.
Components | Description |
---|---|
Domains | Contains SMP and two C2 domains, can bind to small GTPase Rab27A/B |
Main functions | Involved in vesicle transport, exocytosis, extracellular vesicle (exosome) release, cell polarity regulation, etc. |
Cellular localization | Cytoplasm, membrane system, near secretory vesicles |
It may continue to progress without symptoms and eventually develop into locally advanced or metastatic cancer.
Even for localized PCa, treatment methods (such as radical prostatectomy, radiotherapy, etc.) may cause impotence, urinary incontinence, and urination disorders, which will have a long-term impact on the patient's psychology and quality of life.
Some patients with localized PCa are still at risk of biochemical recurrence (increased PSA) after treatment. Recurrence may indicate that cancer cells have spread and the prognosis has worsened.
SYTL2 is upregulated in prostate cancer tissues. High expression is closely related to tumor progression, enhanced metastasis ability, and poor prognosis
PCa cells overexpressing SYTL2 (such as LNCaP, DU145) show stronger migration and invasion ability (Transwell, wound healing assay. After silencing SYTL2 (such as siRNA), the migration ability is significantly reduced.
Promotion of extracellular vesicle (exosome) release happens through regulation of the Rab27A/B-dependent vesicle transport system. Exosomes possess the dual capability of regulating tumor microenvironment conditions and promoting metastatic progression. Integrin recycling is a key part of this process that leads to better cell adhesion and enhanced motility.
Synaptotagmin-like protein 2 (SYTL2) mainly acts as a binding protein for the small GTPase Rab27A/B and plays an important role in vesicle transport, secretion and cell membrane dynamics. Recent studies have shown that SYTL2 has the function of promoting cell migration and invasion in prostate cancer (PCa).
References
Note: If you don't receive our verification email, do the following: